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Botulinum neurotoxins (BoNTs) are proteases that
cleave specific cellular proteins essential for neurotransmit-
ter release. Seven BoNT serotypes (A–G) exist; 4 usually
cause human botulism (A, B, E, and F). We developed a
rapid, mass spectrometry–based method (Endopep-MS) to
detect and differentiate active BoNTs A, B, E, and F. This
method uses the highly specific protease activity of the tox-
ins with target peptides specific for each toxin serotype.
The product peptides derived from the endopeptidase
activities of BoNTs are detected by matrix-assisted laser-
desorption ionization time-of-flight mass spectrometry. In
buffer, this method can detect toxin equivalents of as little
as 0.01 mouse lethal dose (MLD)50 and concentrations as
low as 0.62 MLD50/mL. A high-performance liquid chro-
matography–tandem mass spectrometry method for quan-
tifying active toxin, where the amount of toxin can be
correlated to the amount of product peptides, is also
described.
B
otulinum neurotoxins (BoNTs) are the most toxic sub-
stances known (1). They are produced under anaero-
bic conditions by strains of Clostridium botulinum,  C.
butyricum, and C. baratii (1). Intoxication with 1 of the 7
distinct serotypes of BoNT (A–G) causes botulism. One of
4 serotypes of BoNT (A, B, E, and F) is usually the cause
of botulism in humans. BoNTs are zinc metalloproteases
that cleave and inactivate specific cellular proteins essen-
tial for the release of the neurotransmitter acetylcholine
(Figure 1). BoNT-A, -C, and -E cleave SNAP (synaptoso-
mal-associated protein)-25; BoNT-B, -D, -F, and -G cleave
synaptobrevin 2 (also called VAMP 2). Of the serotypes,
only 1, BoNT-C, cleaves >1 site on a specific protein. In
addition to cleaving SNAP-25, BoNT-C also cleaves syn-
taxin (1).
Current methods for detecting BoNT include a mouse
bioassay (2–4) and an enzyme-linked immunosorbent assay
(ELISA) (5,6). The mouse bioassay is the accepted stan-
dard and is the only widely accepted method for detecting
BoNT(2–5). In this assay, mice receiving an intraperitoneal
injection containing a sample with more than a minimum
lethal dose show symptoms of botulinum intoxication and
die (2,4). Many institutional animal care and use commit-
tees, including that of the Centers for Disease Control and
Prevention, require mice to be euthanized after the onset of
severe symptoms. In the mouse bioassay, when the injected
dose is high, mice typically develop signs of botulism with-
in 8 hours. At lower doses, mice are affected more slowly;
hence, mice are observed for 4 days before a negative result
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Figure 1. Synaptobrevin on the synaptic vesicle must interact with
syntaxin and SNAP (synaptosomal-associated protein)-25 on the
neuronal membrane for fusion to occur, which allows the nerve
impulse to be delivered across the synaptic junction. The botu-
linum neurotoxin serotypes cleave the peptide bonds at specific
sites on the 3 proteins, as indicated. Cleavage of any 1 of these
proteins prevents vesicle membrane docking and nerve impulse
transmission.is recorded. The mouse bioassay can also be used to differ-
entiate BoNT serotypes (4). Mixtures of neutralizing anti-
bodies are given to mice in conjunction with the sample.
Mice receiving the appropriate anti-BoNT serotype anti-
body are asymptomatic and survive, while mice treated
with the other serotype antibodies show symptoms of botu-
lism (4). The mouse bioassay measures active toxin and is
sensitive. The absolute amount of toxin detected in the
mouse bioassay is not well defined but is thought to be
10–20 pg/mL for BoNT A (7,8). The main disadvantage of
the mouse bioassay is that it requires euthanizing many ani-
mals. It also requires several days to determine the toxin
level and type (4–6). Special animal facilities are also
required, personal hazards are associated with injecting ani-
mals (5,6), and some clostridia produce nonbotulinal toxins
that also kill mice (5). 
The ELISA is more rapid than the mouse bioassay, but
it is not a functional assay. It recognizes protein antigenic
sites and in general is somewhat less sensitive than the
mouse bioassay (5,6). The ELISAwas validated for detect-
ing BoNT produced in cooked meat medium and tryptone
peptone glucose yeast extract (TPGY). The test was
designed to detect and differentiate BoNT serotypes A, B,
E, and F in a 1-day test and has the sensitivity of ≈10
mouse lethal dose (MLD)50/mL(5,6). In a recent study, the
ELISA performed well in most laboratories at the 100
MLD50/mLand 10,000 MLD50/mLlevels (5). In this study,
some cross-reactivity occurred among BoNT cultures and
with nonbotulinum cultures (5). At 100 MLD50/mL, a >7%
false-negative rate in TPGY was observed; at 10,000
MLD50/mL, a 1.5% false-positive rate for BoNT-A and a
28.6% false-positive rate for BoNT-F occurred (5). The
ELISAis currently used primarily as a fast screening tech-
nique, and results are verified by the mouse bioassay (5). 
Several in vitro assays have been developed to detect
the activities of the different BoNT serotypes (7–14). This
approach has led to methods that are based on the natural
substrates that are cleaved by the BoNTs and use fluores-
cence to detect toxin activity. These types of assays are >2
orders of magnitude less sensitive than the mouse bioassay
and have not been proven for use with environmental,
food, or clinical samples. They are also prone to giving
false-positive results in samples that contain proteases
because the specific site of cleavage cannot easily be deter-
mined in a fluorescence-based assay (15). Another method
that combines immunoaffinity chromatography with spe-
cific antibodies for cleavage products has been successful
in detecting BoNT B in some foods at lower detection lim-
its than the mouse bioassay (10). 
We introduce here the concept and preliminary data on
a new, rapid, mass spectrometry–based, functional method
for detecting, differentiating, and quantifying 4 BoNT
serotypes. This method is based on both the unusual
endopeptidase activities of these enzymes and specific
detection of the unique peptide products by mass spec-
trometry (Endopep-MS). Because each BoNT serotype has
a unique cleavage site on a unique peptide, the mass-spe-
cific product peptides detected by mass spectrometry dif-
ferentiate active BoNT serotypes. Substrate peptides that
are specific for each serotype are incubated with BoNT;
then serotype-specific product peptides are detected by
either matrix-assisted laser-desorption ionization time-of-
flight mass spectrometry (MALDI-TOF-MS) or by high-
performance liquid chromatography (HPLC)-electrospray
ionization-tandem mass spectrometry (HPLC-
ESI/MS/MS). Thus, this method combines the biologic
specificity of the BoNT enzymatic activity with the unpar-
alleled detection specificity of mass spectrometry. 
Methods
Materials
BoNT complex toxins were purchased from
Metabiologics (Madison, WI, USA) and were provided at
1 mg/mL total protein in 50 mmol/L sodium citrate buffer,
pH 5.5. The toxin activities in MLD50/mg protein were 3.6
× 107 BoNT-A, 1.6 × 107 BoNT-B, 2.8 × 107 BoNT-E, and
5.5 × 107 BoNT-F. All reagents were from Sigma-Aldrich
(St. Louis, MO, USA), except where indicated. HPLC-
purified peptide substrates were synthesized by Los
Alamos National Laboratory (Los Alamos, NM, USA).
Figure 2 shows the peptide sequences used to detect and
differentiate each BoNT serotype along with the specific
cleavage products and their masses. 
Peptide Cleavage Reactions 
For the Endopep-MS method, BoNT serotypes A, B, E,
and F endopeptidase activities were determined in 20-µL
volumes of buffer containing 0.05 mol/L Hepes (pH 7.3),
25 mmol/L dithiothreitol (DTT), 20 mmol/L ZnCl2, 1
mg/mL bovine serum albumin (BSA), and the target pep-
tides, at 1 nmol each. Specific BoNT serotype complexes
were added at various concentrations and incubated at
37ºC from 2 h to 16 h. Control tubes without BoNT were
run at the same time as BoNT cleavage reactions and
served as an analytic blank. The analytic sensitivity of the
reaction was tested by diluting the toxin in Hepes reaction
buffer to 100, 10, 1, 0.1, and 0.01 MLD50/µL. An aliquot
(1 µL) of each dilution was added to 19 µL reaction buffer
containing specific peptides 1–4. 
Multiplexing Reactions
Endopeptidase reactions were multiplexed by adding
all 4 peptides (1–4) at 1 nmol each to the reaction buffer
described above and incubating for 2 h at 37ºC. Each
BoNT serotype was added to separate reaction mixtures.
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time to serve as an analytic blank. High levels of BoNT
(200 ng/20 µL reaction) were used for each serotype to
look for cross-reactivity between any of the BoNT
serotypes. No cross-reactivity between the various BoNT
serotypes was observed.
Detection Limits in MLD50/mL
Larger volume reactions were run to test the sensitivity
in mouse LD50/mL. BoNT serotype A, B, E, or F complex-
es ranging from 100 to 0.31 MLD50 were spiked in 1 mL
of deionized water. A 168-µL aliquot was spiked with a
10× reaction buffer and peptide solution to yield final con-
centrations identical to those above. The target peptides
used for this experiment were the same as above, except
minor modification to the BoNT A and B substrate pep-
tides were used since they showed slightly more activity
than the previous peptides. These peptides were Biotin-(ε)-
KGSNRTRIDEGNQRATR(Nle)LGGK-(ε)-Biotin for
BoNT A and LSELDDRADALQAGASQFESSAAK-
LKRKYWWKNLK for BoNT B. The final reaction vol-
umes were 200 µL. One set of reactions was allowed to
proceed for 4 h, and a second set proceeded for 16 h. The
longer reaction times were used to enhance the amount of
product peptide produced and, therefore, lower the detec-
tion limits. For MALDI-TOF analysis, 2 µL of the 200-µL
reaction mixture was mixed with the matrix and analyzed
as discussed in the MALDI-TOF-MS section. For HPLC-
ESI/MS/MS analysis, 50 µL of the 200-µL reaction mix-
ture was injected on the instrument.
MALDI-TOF-MS Analysis 
Specific cleavage products were detected by mass spec-
trometry. For all experiments, the reaction mixture, at the
incubation times indicated, was added to alpha-cyano-4-
hydroxy cinnamic acid (CHCA) at 5 mg/mL in 50% ace-
tonitrile, 0.1% trifluoroacetic acid, and 1 mmol/L
ammonium citrate (CHCAmatrix), at a ratio of 1:5 or 1:10.
This mixture was applied at 0.5 µL per spot to a 192-spot
stainless steel MALDI plate (Applied Biosystems,
Framingham, MA, USA). Mass spectra of each spot were
obtained by scanning 650–4,500 m/z in MS-positive ion
reflectron mode on a Model 4700 MALDI-TOF-TOF-MS
Proteomics Analyzer (Applied Biosystems). The instru-
ment used a nitrogen laser at 337 nm, and each spectrum
was an average of 2,400 laser shots.
HPLC-ESI/MS/MS Analysis
The HPLC-ESI/MS/MS system consisted of an
API4000 triple quadrupole mass spectrometer with a
TurboIonSpray interface (Applied Biosystems, Toronto,
Canada) and a Shimadzu (Kyoto, Japan) liquid chromato-
graph. We used Luna C18 (Phenomenex, Torrance, CA,
USA) columns (150 mm × 1 mm internal diameter, 5-µm
particles). Solvents were A: H2O with 1% (vol/vol) formic
acid and B: 80:20 acetonitrile:H2O plus 1% (vol/vol)
formic acid. Peptides were eluted with a linear gradient of
0% to 80% solvent B in 25 min, at 50 µL/min. A parallel
column format was used, giving a cycle time of 34 min.
Tandem MS was performed by monitoring precursor to
product transitions under individually optimized condi-
tions, typically from the most abundant [M+nH]n+ precur-
sor ion to an ammonium ion. For BoNT-A, the N-terminal
product 1699.9 m/z, triply charged ion (567.5 m/z) frag-
menting to 84 m/z, was monitored. For BoNT-B, the dou-
bly charged ion (880.7 m/z) fragmenting to 84 m/z was
monitored. For BoNT-E, the C-terminal product (705.8
m/z), doubly charged ion 353.7 → 84.0 amu, was moni-
tored. For BoNT-F, the triply charged ion (587.6 m/z) frag-
menting to 84.1 m/z was monitored. All reaction runs and
transitions were monitored for the entire 32-min run time.
Isotopically labeled product peptides for BoNT-A(432 m/z
→ 70 m/z and 368.8 m/z → 70 m/z) were used as an inter-
nal standard for accurate quantification. 
Results and Discussion
We developed a rapid, sensitive method for detecting
and differentiating BoNT serotypes A, B, E, and F. Each
BoNT serotype recognizes and cleaves a unique site on
either SNAP-25 or VAMP-2 (Figure 1). We synthesized
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Figure 2. Substrate peptide sequences, the botulinum neurotoxin
(BoNT) serotype predicted cleavage product sequences, and
masses of the substrate and product peptides. Peptides for
BoNT-A and -E were derived from the human SNAP (synaptoso-
mal-associated protein)-25 protein. The substrate peptide for
BoNT A, 187-SNKTRIDEANQRATKML-203, was modified to
biotin(ε)-KG(K189->R and K201->R)GGK-(ε)Biotin. The BoNT-E
substrate sequence was also from human SNAP-25 (156–186).
Substrate peptides for BoNT-B and -F are from human synapto-
brevin 2; the BoNT-B substrate (3) is from 59–93 in the sequence
and the BoNT-F substrate is from 35–74.the specific portions of SNAP-25 and VAMP that are sub-
strates for the 4 BoNT serotypes that commonly cause
human botulism (serotypes A, B, E, and F). We used the
endopeptidase activity to detect and differentiate the spe-
cific BoNT serotype by allowing the BoNT to cleave its
specific peptide substrate and detecting the cleavage prod-
ucts by mass spectrometry. 
The substrate peptides were designed to be the same as
the sequences of those portions of the natural SNAP-25
(for BoNT-A and -E) or VAMP (for BoNT-B and -F) that
are recognized and cleaved, except some modifications
were made for BoNT-A and -B. For BoNT-A, the peptide
from SNAP-25 that includes serine-187 to glycine-206 is
required for cleavage at glutamine-196. Schmidt et al.
found that replacing lysines 189 and 201 with arginines
showed enhanced cleavage by BoNT-A (14). We also
found an increase in the amount of BoNT-dependent cleav-
age products detected in the modified peptides. The por-
tion of VAMP-2 required for cleavage by BoNT-B at
glutamine-75 is leucine-59 to lysine-93, and the portion
required for cleavage by BoNT-F at glutamine-57 is from
alanine-36 to serine-74. The portion of SNAP-25 from
isoleucine-156 to aspartic acid-186 is required for cleav-
age between arginine-180 and isoleucine-181 by BoNT-E.
We biotinylated the N and C termini of the substrate pep-
tide for BoNT-Aso that the product peptides of interest can
be easily purified from complex matrices. After final pep-
tide sequences are determined, we plan to biotinylate all
substrate peptides.
The method was multiplexed by combining all 4 sub-
strate peptides for the BoNT serotypes A, B, E, and F into a
sample that contained various levels of a single BoNT
serotype or no toxin. The expected product peptide masses
and the masses of the substrate peptides are shown in Figure
2. The product peptides for each specific BoNT serotype
can be easily distinguished by their mass. The online
Appendix Figure (http://www.cdc.gov/ncidod/EID/vol11
no10/04-1279_app.htm) shows typical results for each of
the reaction mixtures containing the 4 substrate peptides
incubated with only the reaction buffer (a blank) or with 1
of the BoNT serotypes. Each of the BoNT serotypes yield-
ed only the expected cleavage products from its respective
substrate peptides, indicating that this method can easily
detect and differentiate active BoNTserotypes. No cleavage
was observed in the reactions that did not contain BoNT.
Additionally, even at this relatively high toxin level, no
cross-reactivity was seen between the toxin types; only the
expected peptide cleavage reactions were observed.  
We also tested sensitivity of the method for each single
toxin serotype with a single substrate peptide. Since enzy-
matic reactions tend to be concentration dependent, this
testing was accomplished in 2 ways. First, we determined
the sensitivity on the basis of the lowest absolute amount
of toxin that could be detected by the Endopep-MS method
in a 20-µLreaction; second, we determined the lowest con-
centration per milliliter that could be detected by this
method. The first approach indicates the minimum amount
of toxin that needs to be present, and the second indicates
the minimum concentration of toxin in a sample. For
BoNT serotypes A, B, and F as little as 0.01 MLD50 yield-
ed sufficient quantities of product peptides to be clearly
detected by MALDI-TOF-MS. This figure is 100× lower
in the absolute amount of toxin than that required by the
mouse bioassay. For BoNT-E, product peptides could be
detected by MALDI-TOF-MS with as little as 0.08
MLD50. The analytic sensitivity of the method was then
tested to determine the lowest measurable concentration of
the toxin. An aliquot of a 1-mL sample that contained 100
MLD50 to 0.31 mouse LD50 in water was tested by both the
MALDI-TOF-MS and HPLC-ESI/MS/MS methods.
Reactions were also allowed to proceed for 4 h and for 16
h. The 4-h reactions for BoNT-A, -B, and -E showed the
sensitivity by MALDI-TOF-MS detection of the product
peptides of 1.2 mouse LD50/mL for BoNT-A and -B and
6.2 mouse LD50/mL for BoNT-E. After 16-h reactions, the
sensitivity was 0.62 mouse LD50/mL for BoNT-A and -B,
0.31 mouse LD50/mLfor BoNT-E, and 6.2 mouse LD50/mL
for BoNT-F. Using HPLC-ESI/MS/MS to analyze these
same low toxin samples, we found that after 16-h incuba-
tion, the detection limits were 0.62 mouse LD50/mL for
BoNT-A and -B, <0.31 MLD50/mL for BoNT-E, and 0.62
MLD50/mL for BoNT-F. These data indicate that the
Endopep-MS method is very sensitive with respect to the
amount and concentration of toxin and that methods that
can concentrate active toxins into smaller reaction vol-
umes (thus yielding higher concentration) will result in
lower limits of detection. 
The HPLC-ESI/MS/MS technique to quantitatively
detect and differentiate BoNT activities is highly selective.
Correct identification of the BoNT product peptides
depends on both a retention time match, with respect to
standards, and on a chemical-specific fragmentation (a
precursor to product ion multiple reaction monitoring
[MRM] transition) monitored by tandem MS. To further
enhance selectivity, 2 separate MRM transitions can be
monitored for each peptide. In addition, our HPLC-
ESI/MS/MS technique is very sensitive. Quantification of
the BoNT product peptides is achieved by using stable iso-
tope-labeled internal standards that have the same
sequence as the native product peptides but are labeled
with 13C. Figure 3 shows typical HPLC-ESI/MS/MS chro-
matograms obtained during the quantification of the activ-
ity of BoNT-A, and a standard curve for both of the
product peptides. The amount of product peptide was then
correlated with the amount of toxin that yielded the
product peptides. Standard curves between 10 and 1,000
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run as unknown samples to determine the accuracy and
precision of the method. The spiked samples were pre-
pared at 16, 32, 65, and 125 MLD50; 2 samples were run in
duplicate at each spike level giving a total of 4 measure-
ments. The accuracy and precision of these measurements,
shown in the Table, were good; relative standard devia-
tions were <2%–5%. This method is the first that can accu-
rately quantify BoNT enzymatic activity. Identical
HPLC-ESI/MS/MS strategies can be used to quantify each
of the BoNT serotypes. 
The Endopep-MS method has many possible applica-
tions. Beyond using the Endopep-MS method for identify-
ing the BoNT serotype in a clinical, food, or environmental
sample, standardizing BoNT activity in samples used for
clinical treatment or research activities may be possible.
The standardization of BoNT, both the amount of 150-kDa
toxin and the activity of a standard solution, is of great
importance in the medical use of BoNT (16). A possible
strategy for standardizing BoNT includes correlating the
activity obtained by the mouse bioassay to the Endopep-MS
method. Additionally, it may be possible to correlate this
activity to an absolute amount of toxin that is determined in
a similar fashion as was done for apolipoprotein A-1 (17).
Endopep-MS currently has limitations. Mass spectrom-
etry equipment is expensive and requires a high level of
technical expertise for optimal operation. The method still
needs to be tested in a wide variety of clinical and food
samples and may require the use of protease inhibitors and
affinity chromatography to partially purify and concentrate
the toxin. Also, the Endopep-MS method needs to be vali-
dated against the mouse bioassay. The method also has
several strengths. It is rapid, and in simple matrices, such
as water and buffer, it can obtain similar sensitivities to the
mouse in <5 h. Samples can be prepared for the reactions
in minutes; incubation times of only 4 h yield sensitivity
close to the mouse bioassay, and MALDI-TOF mass spec-
tra can be collected in <1 min. Samples can also be
batched so that 50 samples can be analyzed in <6 h. The
HPLC-ESI/MS/MS analysis is somewhat slower than the
MALDI-TOF-MS, and each sample requires 30 min.
However, this process has been automated, and batches of
samples can run unattended so that 40 samples a day can
be processed and run by HPLC-ESI/MS/MS. The method
is well suited for multiplexing and can not only detect but
also differentiate toxin type in a single analytic run. 
Conclusions
We developed a method based on the unusually specif-
ic endopeptidase activity of BoNT that uses highly selec-
tive mass spectrometry analysis to detect and differentiate
BoNT serotypes A, B, E and F. This method is rapid and
sensitive. When the endopeptidase reactions are allowed to
proceed for 16 h, it is highly sensitive; 100× more sensitive
in absolute amounts of active toxin for BoNT-A, -B,
and -F and >10× more sensitive than the mouse bioassay
for BoNT-E. Since each BoNT serotype has a unique
cleavage site on a substrate peptide, this analysis lends
itself well to multiplexing. We multiplexed the analysis
and showed that no cross-reactivity occurs within the 4
BoNT serotypes. The Endopep-MS method should be very
useful to rapidly detect and differentiate active BoNT in a
variety of clinical, food, or environmental samples to
quickly establish the serotype(s) and aid in identifying a
source during an outbreak. It may also prove useful for
standardizing BoNT enzymatic activity for preparations
used as clinical treatments or for research activities. This
type of approach may also prove useful for detecting other
proteolytic toxins.
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Figure 3. High-performance liquid chromatography-electrospray
ionization-tandem mass spectrometry chromatogram showing the
botulinum neurotoxin (BoNT)-A substrate and product ions (CT, C-
terminal; NT, N-terminal) from a reaction with 25 mouse lethal
dose (MLD)50 BoNT-A. Each peptide has both a quantification ion
(top trace) and a verification ion (lower trace). Isotopically labeled
standards are added (traces not shown) as internal standards for
quantification. The labeled peptides co-elute with their nonlabeled
counterparts and are distinguishable by mass. Leucine enkephalin
was included as a secondary reference compound and only 1 ion
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contract at the Centers for Disease Control and Prevention,
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